3rd Meeting of OIC – Vaccine Manufacturers Group

The conclusion of Millenium Development Goals agenda in 2015 was continued by Sustainable Development Goals (SDGs) agenda which comprised 17 goals with 169 targets expected to achieve in 2030. Indonesia is committed to taking part in achieving the target. Those goals are largely associated with health where Indonesia will continue providing valuable contribution to the domestic and global demand.

World Health Organization (WHO) is discussing various strategies and policies in its efforts to improve health which includes prevention from communicable diseases. WHO recommends vaccine as the most effective form of prevention from dangerous and communicable diseases.

Indonesia has the competence and skills to produce vaccines with the world’s recognition. At the meeting of OIC vaccine manufacturer at Bandung on June 2013, there was reached an agreement on the necessity to establish OIC Vaccine Manufacturer Group (VMG).

Indonesian vaccine products have been globally recognized with qualification from WHO for OPV, mOPV1, bOPV (1 and 3), measles 10 ds, measles 20 ds, DT, DTP, TT (vial), Td, TT(uniject), Hep B (uniject), DTP-HepB and Pentabio (DTP-HepB-Hib).

The coordination and cooperation among various institutions involved has allowed Indonesia to become one of the countries to play important role in the world also among the Islamic countries joining the Organization of Islamic Cooperation (OIC). Indonesia’s presence in OIC is to act as the leading country to implement green economy (vaccine innovation).

The purpose of this training is to support self-reliance of vaccine of Islamic countries to produce EPI vaccines, including the administration and handling of vaccines.

Various important topics to be discussed in this training include Capacity Building and Training on Vaccine Regulatory System, Role and Policy of World Health Organization (WHO), included requirement for licensing and regular inspection for GMP, Update disease control and environmental health, Role and Policy of National Regulatory Affairs (NRA), included system of lot release, and . Review on new vaccine product for Expanded Program on Immunization (EPI).

In addition, the training will also cover issues on Capacity Building and Training on Quality Management System (QMS) in terms of documentation, validation corrective and preventive management.

Besides the 4-day training with in-class activities, exercise and visit to vaccine industrial facilities will also be carried out through social-culture program in West Java.